These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 22057727)

  • 1. Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.
    Smith JR; Rayner CR; Donner B; Wollenhaupt M; Klumpp K; Dutkowski R
    Adv Ther; 2011 Nov; 28(11):927-59. PubMed ID: 22057727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
    Widmer N; Meylan P; Ivanyuk A; Aouri M; Decosterd LA; Buclin T
    Clin Pharmacokinet; 2010 Nov; 49(11):741-65. PubMed ID: 20923248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.
    Toovey S; Rayner C; Prinssen E; Chu T; Donner B; Thakrar B; Dutkowski R; Hoffmann G; Breidenbach A; Lindemann L; Carey E; Boak L; Gieschke R; Sacks S; Solsky J; Small I; Reddy D
    Drug Saf; 2008; 31(12):1097-114. PubMed ID: 19026027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oseltamivir resistance among influenza viruses: surveillance in northern Viet Nam, 2009-2012.
    Hoang Vu MP; Nguyen CT; Nguyen le KH; Nguyen TK; Le QM
    Western Pac Surveill Response J; 2013; 4(2):25-9. PubMed ID: 24015368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir.
    Reddy D
    J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii35-ii40. PubMed ID: 20215134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oseltamivir in the management of influenza.
    Oxford J
    Expert Opin Pharmacother; 2005 Nov; 6(14):2493-500. PubMed ID: 16259580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza viruses resistant to neuraminidase inhibitors.
    Nitsch-Osuch A; Brydak LB
    Acta Biochim Pol; 2014; 61(3):505-8. PubMed ID: 25195142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed emergence of oseltamivir-resistant seasonal influenza A (H1N1) and pandemic influenza A(H1N1)pdm09 viruses in Myanmar.
    Dapat C; Saito R; Kyaw Y; Myint YY; Oo HN; Oo KY; Naito M; Hasegawa G; Dapat IC; Suzuki H
    Influenza Other Respir Viruses; 2013 Sep; 7(5):766-71. PubMed ID: 23122276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.
    Dutkowski R
    J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii11-ii24. PubMed ID: 20215131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza virus susceptibility and resistance to oseltamivir.
    Aoki FY; Boivin G; Roberts N
    Antivir Ther; 2007; 12(4 Pt B):603-16. PubMed ID: 17944268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza in the tropics.
    Moura FE
    Curr Opin Infect Dis; 2010 Oct; 23(5):415-20. PubMed ID: 20644472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.
    Hurt AC; Holien JK; Parker MW; Barr IG
    Drugs; 2009; 69(18):2523-31. PubMed ID: 19943705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuraminidase amino acids 149 and 347 determine the infectivity and oseltamivir sensitivity of pandemic influenza A/H1N1 (2009) and avian influenza A/H5N1.
    Yongkiettrakul S; Nivitchanyong T; Pannengpetch S; Wanitchang A; Jongkaewwattana A; Srimanote P
    Virus Res; 2013 Aug; 175(2):128-33. PubMed ID: 23639424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the optimal therapy for patients with H5N1 influenza?
    White NJ; Webster RG; Govorkova EA; Uyeki TM
    PLoS Med; 2009 Jun; 6(6):e1000091. PubMed ID: 19554084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.
    McKimm-Breschkin JL
    Influenza Other Respir Viruses; 2013 Jan; 7 Suppl 1(Suppl 1):25-36. PubMed ID: 23279894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.
    Dixit R; Khandaker G; Ilgoutz S; Rashid H; Booy R
    Infect Disord Drug Targets; 2013 Feb; 13(1):34-45. PubMed ID: 23675925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010.
    Hurt AC; Deng YM; Ernest J; Caldwell N; Leang L; Iannello P; Komadina N; Shaw R; Smith D; Dwyer DE; Tramontana AR; Lin RT; Freeman K; Kelso A; Barr IG
    Euro Surveill; 2011 Jan; 16(3):. PubMed ID: 21262183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture].
    Fediakina IT; Shchelkanov MIu; Deriabin PG; Leneva IA; Gudova NV; Kondrat'eva TV; L'vov DK
    Antibiot Khimioter; 2011; 56(3-4):3-9. PubMed ID: 21913403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.
    Sheu TG; Deyde VM; Okomo-Adhiambo M; Garten RJ; Xu X; Bright RA; Butler EN; Wallis TR; Klimov AI; Gubareva LV
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3284-92. PubMed ID: 18625765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.